Recently, albumin-myosteatosis gauge (AMG) has been proposed as a novel skeletal muscle-related marker in colorectal and pancreatic cancer [49,50], with low pre-treatment AMG levels reported to worsen prognosis. The gene discussed is ALB; the disease is pancreatic neoplasm.